About Ultimovacs

Ultimovacs is a small pharmaceutical company developing novel immunotherapy against cancer. Our leading product is UV1, a therapeutic cancer vaccine (TCV) directed against human telomerase (hTERT). The vaccine is a result of many years of pre-clinical and clinical research at the Norwegian Radium Hospital. UV1 is a synthetic peptide vaccine.
The peptides included in the vaccine is based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.

The company is focusing on two ongoing clinical trials where we are documenting safety and the vaccines ability to activate the immune system against cancer cells expressing the hTERT fragments that are the components of the vaccine.

Ultimovacs will also start a third clinical trial assessing safety and clinical outcomes when combining UV1 with ipilimumab in patients with malignant melanoma.

Ultimovacs is owned by Gjelsten Holding, The Norwegian Radium Hospital Research Foundation and Inven2 and is located in Oslo Science Park, Oslo, Norway.

Management

Board of Directors